The firm deepens its 130-year presence in Baltimore and commitment to driving inclusive economic growth; advances $20 million five-year philanthropic commitment to BaltimoreJune 4, 2024 (Baltimore) – Today, JPMorgan Chase announced an $8.45 million philanthropic commitment to nonprofit organizations and programs across the city of Baltimore to support economic and community development. Specifically, the firm’s funding will address residential vacancies to stabilize housing supply and promote access to affordable homeownership; support commercial corridor revitalization; and promote small business growth. This announcement is the latest round of funding as part of the firm’s $20 million five-year commitment to benefit underserved communities across the city.
The philanthropic investments include:
- $6 million to stabilize housing supply and increase access to affordable homeownership: The firm will commit new philanthropic capital to nonprofit organizations addressing housing vacancy in Baltimore, with a specific focus on those investing in neighborhood stabilization efforts, building wealth in underserved communities and increasing the affordable housing supply. Several local organizations working across the city have been invited to apply for this funding and the firm will select recipients working at varying levels of program implementation and capacity in late 2024.
Montgomery County: A Life Sciences Hub According to Pete Briskman, Chair of BHI’s Board of Directors
Montgomery County, Maryland, is a top destination for the life sciences industry. Pete Briskman, JLL’s Executive Managing Director and Chair of BioHealth Innovation Inc.’s (BHI) Board of Directors, highlights several reasons why.
“Montgomery County is poised well in comparison to other regions,” Briskman said, pointing to its proximity to NIH and FDA and the strong talent pipeline from local universities.
Briskman also emphasized creative real estate solutions and the region’s strengths in cell and immunotherapy research. “Health care isn’t going away,” he noted, reflecting optimism about the sector’s growth.
Venlo, the Netherlands, and Salt Lake City, Utah, May 30, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. This next-generation sequencing (NGS) test aims to support research into personalized medicine in multiple solid tumor types, including ovarian cancer and is expected to enhance decentralized testing capacities once a regulated product is developed with pharmaceutical partners. The project builds on the recently announced master collaboration agreement between the two companies.
Washington, D.C., June 03, 2024 (GLOBE NEWSWIRE) — Children’s National Hospital is pleased to welcome Alda Mizaku in a newly established role of vice president and chief data and artificial intelligence officer (CDAIO). In this role, Mizaku will lead the execution of enterprise data, analytics and artificial intelligence (AI) strategy at Children’s National.
Mizaku has a track record of leading initiatives with measurable organizational value, from reducing unnecessary length of stay to enhancing operational efficiency and patient outcomes. Prior to joining Children’s National, Mizaku spent 11 years working for Mercy Health System in St. Louis, where she served in various roles, including executive director of Data Engineering and Analytics, and vice president of Analytics Product Management.
AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody.
The planned greenfield facility, supported by the Singapore Economic Development Board (EDB), will be AstraZeneca’s first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale. Manufacturing of ADCs is a multi-step process that comprises antibody production, synthesis of chemotherapy drug and linker, conjugation of drug-linker to the antibody, and filling of the completed ADC substance.
Did you know? Each year, the federal government dedicates around $3.6 billion towards SBIR and STTR programs, resulting in awards to over 5,000 innovative projects!
The next deadline for NIH SBIR/STTR proposals is September 5th. As an innovation intermediary, BioHealth Innovation (BHI) is here to help you secure federal funding.
If you’re seeking assistance, don’t hesitate to reach out to Jon Nelson at JNelson@BioHealthInnovation.org. Let’s innovate together!
At BioHealth Innovation Inc. (BHI), we are happy to celebrate the achievements of our partner company, miRecule, which has recently been named a winner at the INVEST Pitch Perfect competition. miRecule’s innovative approach to RNA therapies represents a significant advance in the treatment of cancer and muscular dystrophy. By leveraging genomic data to design highly specific therapeutics, miRecule stands at the forefront of personalized medicine, underscoring our commitment to supporting ground-breaking healthcare solutions.
This recognition is not just a win for miRecule; it’s a testament to the power of strategic partnerships and the impact of innovative biotechnological advances in addressing complex health challenges. BHI is proud to be associated with pioneers like miRecule, as we continue to foster a thriving ecosystem that brings revolutionary treatments from the lab to the patients who need them most.
Join us for an enlightening episode of BioTalk with Rich Bendis, featuring Michael J. Tarlov, Chief of the Biomolecular Measurement Division at the Material Measurement Laboratory, NIST. With a distinguished career in analytical chemistry and extensive experience in biochemical sensing and bioprocess measurements, Michael leads critical initiatives to advance biotechnology and healthcare.
In this episode, we delve into the pivotal role of NIST as a non-regulatory agency within the Department of Commerce, highlighting its profound impact on measurement science, gene therapy, gene editing, synthetic biology, and regenerative medicine. Michael shares insights into NIST’s collaborations, including local companies like MedImmune/AstraZeneca and Novavax, and the importance of partnerships with academic institutions like the University of Maryland in driving local biotech advancements.
Listen now via:
- Apple: https://apple.co/45acj2V
- Spotify: https://spoti.fi/3KpFmGj
- Amazon Music: https://amzn.to/3yL7oJK
- TuneIn: https://bit.ly/45bPT1s
COLUMBIA, Md., (May 29, 2024) — TEDCO, Maryland’s economic engine for technology companies, unveiled the recently completed “Cybersecurity Workforce Analysis and Study” (“Study”). The Study was commissioned by TEDCO to better understand the current status of Maryland’s cybersecurity workforce pipeline. This knowledge will be used to guide the Cyber Maryland Program (“Program”) and its 18-member board of directors as they develop a statewide cybersecurity workforce development strategic plan.
“The Study confirms what businesses and government agencies in Maryland already know: demand for skilled cybersecurity professionals—who protect our communities from criminals threatening our way of life—is incredibly nuanced. Thankfully, there is support and momentum amongst key stakeholders to bridge our talent gap,” said Roger Austin, chair of the Cyber Maryland board of directors. “My fellow board members and I are committed to address this critical need by developing innovative solutions to overcome our cyber skills talent gaps and provide good, paying jobs for our state’s residents.”
COLUMBIA, Md. (May 30, 2024) – The Maryland Stem Cell Research Commission (“the Commission”) announces the release of Requests for Applications (RFAs) for the Maryland Stem Cell Research Fund’s (MSCRF) first funding cycle of fiscal year 2025 (FY25).
RFAs for this initial cycle are now available for five grant programs: Manufacturing Assistance, Clinical, Validation, Commercialization, and Launch. All applications are due by July 9, 2024.
Along with this announcement comes the news that the Commission is also extending grant funding to businesses outside of Maryland for the Commercialization grant program, provided the research activities are conducted within the State. The Clinical grant program is available to entities with at least one clinical site in Maryland.